These findings are especially interesting, since PARP-1 inhibitors (PARPi) are already used in clinical trials and showed good efficiency, notably in ovarian and breast cancers where ETS proteins are often overexpressed [6,30,31,32]. The gene discussed is PARP1; the disease is breast carcinoma.